Pipeline | Almirall
Pipeline
At Almirall, we are committed to transforming the lives of patients through innovative research and development. Our pipeline represents a broad array of groundbreaking therapies, each designed to address some of the most pressing medical needs in dermatology.
Late stage pipeline
This dynamic pipeline showcases our dedication to advancing treatment options, leveraging cutting-edge science and technology to bring new solutions to the market. Here, you can explore our Late-stage pipeline, where we focus on delivering therapies that promise to make a meaningful impact on patient care.
Last update: 29 July 2026
| Name | Indication | Type | Phase | Region |
|---|---|---|---|---|
| Tirbanibulin | Actinic keratosis | Life-cycle management | Registration | European Union |
| Lebrikizumab | Paediatric atopic dermatitis | Life-cycle management | Phase III | European Union |
| Lebrikizumab | Nummular eczema | Life-cycle management | Phase III | European Union |
| Anti-IL-1RAP mAb | Hidradenitis suppurativa | New Molecular Entity | Phase II | Worldwide |
| Anti-IL-1RAP mAb | Inflammatory skin disease | New Molecular Entity | Phase II | Worldwide |
| Anti-IL-21 mAb | Hidradenitis suppurativa | New Molecular Entity | Phase II | Worldwide |
| IL-2muFc | SLE with cutaneous manifestations | New Molecular Entity | Phase II | Worldwide |
| IL-2muFc | Atopic dermatitis | New Molecular Entity | Phase II | Worldwide |
| IL-2muFc | Alopecia areata | New Molecular Entity | Phase II | Worldwide |
| Readthrough inducer | Rare dermatology (RDEB/JEB) | New Molecular Entity | Phase I | Worldwide |
| Anti-IL-13/OX40L BsAb | Atopic dermatitis | New Molecular Entity | Phase I | Worldwide |
| SMOL oral | Th2-driven diseases | New Molecular Entity | Preclinical | Worldwide |
| mRNA/LNP | Non-melanoma skin cancer | New Molecular Entity | Preclinical | Worldwide |